ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Eisai reboots search for blockbuster Alzheimer's drug

Failure to strike gold with Aduhelm prompts renewed focus on successor

Eisai has been the only Japanese pharmaceutical company with a heavy focus on neurocognitive disorders. (Photo by Kosaku Mimura)

TOKYO -- Japanese pharmaceutical group Eisai has essentially given up on a prospective blockbuster Alzheimer's disease drug and will instead focus resources on developing a follow-up offering.

Eisai had expected Aduhelm to generate more than 100 billion yen ($846 million) in annual revenue. The U.S. Food and Drug Administration granted conditional approval to the drug in June 2021.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more